Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model.

Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L.

Science. 2007 May 4;316(5825):750-4.

2.

Mouse models of Alzheimer's disease: the long and filamentous road.

Phinney AL, Horne P, Yang J, Janus C, Bergeron C, Westaway D.

Neurol Res. 2003 Sep;25(6):590-600. Review.

PMID:
14503012
3.

Alzheimer disease therapy--moving from amyloid-β to tau.

Giacobini E, Gold G.

Nat Rev Neurol. 2013 Dec;9(12):677-86. doi: 10.1038/nrneurol.2013.223. Epub 2013 Nov 12. Review.

PMID:
24217510
4.

Probing the biology of Alzheimer's disease in mice.

Ashe KH, Zahs KR.

Neuron. 2010 Jun 10;66(5):631-45. doi: 10.1016/j.neuron.2010.04.031. Review.

5.

Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease.

Ittner LM, Götz J.

Nat Rev Neurosci. 2011 Feb;12(2):65-72. doi: 10.1038/nrn2967. Epub 2010 Dec 31. Review.

PMID:
21193853
6.

Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis.

Small SA, Duff K.

Neuron. 2008 Nov 26;60(4):534-42. doi: 10.1016/j.neuron.2008.11.007. Review.

7.

The 12/15-lipoxygenase as an emerging therapeutic target for Alzheimer's disease.

Joshi YB, Giannopoulos PF, Praticò D.

Trends Pharmacol Sci. 2015 Mar;36(3):181-186. doi: 10.1016/j.tips.2015.01.005. Epub 2015 Feb 20. Review.

8.

In-vivo visualization of key molecular processes involved in Alzheimer's disease pathogenesis: Insights from neuroimaging research in humans and rodent models.

Higuchi M, Maeda J, Ji B, Maruyama M, Okauchi T, Tokunaga M, Ono M, Suhara T.

Biochim Biophys Acta. 2010 Apr;1802(4):373-88. doi: 10.1016/j.bbadis.2010.01.003. Epub 2010 Jan 12. Review.

9.

Endogenous glucocorticoids: role in the etiopathogenesis of Alzheimer's disease.

Libro R, Bramanti P, Mazzon E.

Neuro Endocrinol Lett. 2017 Feb;38(1):1-12. Review.

PMID:
28456142
10.

Models of β-amyloid induced Tau-pathology: the long and "folded" road to understand the mechanism.

Stancu IC, Vasconcelos B, Terwel D, Dewachter I.

Mol Neurodegener. 2014 Nov 18;9:51. doi: 10.1186/1750-1326-9-51. Review.

11.

Alzheimer's disease in a dish: promises and challenges of human stem cell models.

Young JE, Goldstein LS.

Hum Mol Genet. 2012 Oct 15;21(R1):R82-9. Epub 2012 Aug 2. Review.

12.

A 'danse macabre': tau and Fyn in STEP with amyloid beta to facilitate induction of synaptic depression and excitotoxicity.

Boehm J.

Eur J Neurosci. 2013 Jun;37(12):1925-30. doi: 10.1111/ejn.12251. Review.

PMID:
23773061
13.

Alzheimer's disease; taking the edge off with cannabinoids?

Campbell VA, Gowran A.

Br J Pharmacol. 2007 Nov;152(5):655-62. Epub 2007 Sep 10. Review.

14.

Phospholipase A2 and arachidonic acid in Alzheimer's disease.

Sanchez-Mejia RO, Mucke L.

Biochim Biophys Acta. 2010 Aug;1801(8):784-90. doi: 10.1016/j.bbalip.2010.05.013. Epub 2010 May 27. Review.

15.

Animal models reveal role for tau phosphorylation in human disease.

Götz J, Gladbach A, Pennanen L, van Eersel J, Schild A, David D, Ittner LM.

Biochim Biophys Acta. 2010 Oct;1802(10):860-71. doi: 10.1016/j.bbadis.2009.09.008. Epub 2009 Sep 12. Review.

16.

Dietary arachidonic acid as a risk factor for age-associated neurodegenerative diseases: Potential mechanisms.

Thomas MH, Pelleieux S, Vitale N, Olivier JL.

Biochimie. 2016 Nov;130:168-177. doi: 10.1016/j.biochi.2016.07.013. Epub 2016 Jul 26. Review.

PMID:
27473185
17.

Alzheimer disease, the two-hit hypothesis: an update.

Zhu X, Lee HG, Perry G, Smith MA.

Biochim Biophys Acta. 2007 Apr;1772(4):494-502. Epub 2006 Oct 27. Review.

18.

Leptin: a novel therapeutic strategy for Alzheimer's disease.

Tezapsidis N, Johnston JM, Smith MA, Ashford JW, Casadesus G, Robakis NK, Wolozin B, Perry G, Zhu X, Greco SJ, Sarkar S.

J Alzheimers Dis. 2009;16(4):731-40. doi: 10.3233/JAD-2009-1021. Review.

Supplemental Content

Support Center